Compliance with good manufacturing practice (“GMP”) is mandatory for all medicinal products that have been granted a marketing authorisation. Likewise, the manufacture of investigational medicinal products must be in accordance with GMP. Advanced therapy medicinal products that are administered to patients under Article 3 of Directive 2001/83/EC (so called “hospital exemption”) must be manufactured under equivalent quality standards to the manufacturing of advanced therapy medicinal products with a marketing authorisation.
Article 5 of Regulation (EC) No 1394/2007 mandates the Commission to draw up guidelines on good manufacturing practice specific to advanced therapy medicinal products ("ATMPs"). Article 63(1) of Regulation (EU) No 536/2014 also empowers the Commission to adopt and publish detailed guidelines on good manufacturing practice applicable to investigational medicinal products.
EC 22.11.2017
EudraLex 22.11.2017
della Commissione del 28 giugno 2021 che approva il cloruro di alchil (C12-16) dimetilbenzilammonio come principio attivo ai fini del suo uso nei biocidi dei ti...
Rapporto ISTISAN 17|13
Atti
Questo rapporto raccoglie i contributi al convegno, "RInnovaReNano: sviluppo respons...
Ministero della Salute, 2021
La Legge 7 agosto 1986, 462 recante “misure urgenti in materia di prevenzione e repressione delle ...
Testata editoriale iscritta al n. 22/2024 del registro periodici della cancelleria del Tribunale di Perugia in data 19.11.2024
